APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anxiety Disorders And Depression Therapeutic Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anxiety Disorders And Depression Therapeutic Drug Market Outlook and Growth Opportunities 2026

19 December 2025204 pages

Choose your research edition.

Industry ResearchAnxiety Disorders And Depression Therapeutic Drug Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Anxiety Disorders And Depression Therapeutic Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Anxiety Disorders And Depression Therapeutic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anxiety Disorders And Depression Therapeutic Drug Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Anxiety Disorders And Depression Therapeutic Drug Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Anxiety Disorders And Depression Therapeutic Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anxiety Disorders And Depression Therapeutic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anxiety Disorders And Depression Therapeutic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anxiety Disorders And Depression Therapeutic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anxiety Disorders And Depression Therapeutic Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anxiety Disorders And Depression Therapeutic Drug market include Takeda, Sanofi, Johnson & Johnson, Eli Lilly, Pfizer, GSK, AstraZeneca, Zhejiang Huahai and Shionogi, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Anxiety Disorders And Depression Therapeutic Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anxiety Disorders And Depression Therapeutic Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anxiety Disorders And Depression Therapeutic Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anxiety Disorders And Depression Therapeutic Drug market.

Anxiety Disorders And Depression Therapeutic Drug Segment by Company

Takeda

Sanofi

Johnson & Johnson

Eli Lilly

Pfizer

GSK

AstraZeneca

Zhejiang Huahai

Shionogi

Otsuka Pharmaceutical

Merck & Co. Inc

Lundbeck

Kanghong Pharma

Bristol-Myers Squibb Company

APOTEX

Allergan

Anxiety Disorders And Depression Therapeutic Drug Segment by Type

Anticonvulsants

Atypical Antipsychotics

Benzodiazepines

Beta-Blockers

TeCAs

TCAs

SSRIs

SNRIs

MAOIs

Others

Anxiety Disorders And Depression Therapeutic Drug Segment by Application

Phobia

Obsessive-Compulsive Disorder (OCD)

Major Depressive Disorder (MDD)

Others

Anxiety Disorders And Depression Therapeutic Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Anxiety Disorders And Depression Therapeutic Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Anxiety Disorders And Depression Therapeutic Drug key companies, revenue, market share, and recent developments.

3. To split the Anxiety Disorders And Depression Therapeutic Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Anxiety Disorders And Depression Therapeutic Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anxiety Disorders And Depression Therapeutic Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Anxiety Disorders And Depression Therapeutic Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anxiety Disorders And Depression Therapeutic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anxiety Disorders And Depression Therapeutic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anxiety Disorders And Depression Therapeutic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anxiety Disorders And Depression Therapeutic Drug industry.

Chapter 3: Detailed analysis of Anxiety Disorders And Depression Therapeutic Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Anxiety Disorders And Depression Therapeutic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Anxiety Disorders And Depression Therapeutic Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anxiety Disorders And Depression Therapeutic Drug Industry Trends Table 2. Anxiety Disorders And Depression Therapeutic Drug Industry Drivers Table 3. Anxiety Disorders And Depression Therapeutic Drug Industry Opportunities and Challenges Table 4. Anxiety Disorders And Depression Therapeutic Drug Industry Restraints Table 5. Global Anxiety Disorders And Depression Therapeutic Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anxiety Disorders And Depression Therapeutic Drug Revenue Share by Company (2021-2026) Table 7. Global Anxiety Disorders And Depression Therapeutic Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Anxiety Disorders And Depression Therapeutic Drug Key Company Manufacturing Base & Headquarters Table 9. Global Anxiety Disorders And Depression Therapeutic Drug Company, Product Type & Application Table 10. Global Anxiety Disorders And Depression Therapeutic Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Anxiety Disorders And Depression Therapeutic Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Anticonvulsants Table 15. Significant Companies of Atypical Antipsychotics Table 16. Significant Companies of Benzodiazepines Table 17. Significant Companies of Beta-Blockers Table 18. Significant Companies of TeCAs Table 19. Significant Companies of TCAs Table 20. Significant Companies of SSRIs Table 21. Significant Companies of SNRIs Table 22. Significant Companies of MAOIs Table 23. Significant Companies of Others Table 24. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type (2021-2026) Table 28. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Phobia Table 30. Significant Companies of Obsessive-Compulsive Disorder (OCD) Table 31. Significant Companies of Major Depressive Disorder (MDD) Table 32. Significant Companies of Others Table 33. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Application (2021-2026) & (US$ Million) Table 35. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Application (2027-2032) & (US$ Million) Table 36. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application (2021-2026) Table 37. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application (2027-2032) Table 38. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Region (2021-2026) & (US$ Million) Table 40. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Region (2021-2026) Table 41. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Region (2027-2032) & (US$ Million) Table 42. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Region (2027-2032) Table 43. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Country (2021-2026) & (US$ Million) Table 45. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Market Share by Country (2021-2026) Table 46. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Country (2027-2032) & (US$ Million) Table 47. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Market Share by Country (2027-2032) Table 48. Takeda Company Information Table 49. Takeda Business Overview Table 50. Takeda Anxiety Disorders And Depression Therapeutic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Takeda Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 52. Takeda Recent Development Table 53. Sanofi Company Information Table 54. Sanofi Business Overview Table 55. Sanofi Anxiety Disorders And Depression Therapeutic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Sanofi Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 57. Sanofi Recent Development Table 58. Johnson & Johnson Company Information Table 59. Johnson & Johnson Business Overview Table 60. Johnson & Johnson Anxiety Disorders And Depression Therapeutic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Johnson & Johnson Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 62. Johnson & Johnson Recent Development Table 63. Eli Lilly Company Information Table 64. Eli Lilly Business Overview Table 65. Eli Lilly Anxiety Disorders And Depression Therapeutic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Eli Lilly Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 67. Eli Lilly Recent Development Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Anxiety Disorders And Depression Therapeutic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Pfizer Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 72. Pfizer Recent Development Table 73. GSK Company Information Table 74. GSK Business Overview Table 75. GSK Anxiety Disorders And Depression Therapeutic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. GSK Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 77. GSK Recent Development Table 78. AstraZeneca Company Information Table 79. AstraZeneca Business Overview Table 80. AstraZeneca Anxiety Disorders And Depression Therapeutic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. AstraZeneca Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 82. AstraZeneca Recent Development Table 83. Zhejiang Huahai Company Information Table 84. Zhejiang Huahai Business Overview Table 85. Zhejiang Huahai Anxiety Disorders And Depression Therapeutic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Zhejiang Huahai Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 87. Zhejiang Huahai Recent Development Table 88. Shionogi Company Information Table 89. Shionogi Business Overview Table 90. Shionogi Anxiety Disorders And Depression Therapeutic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Shionogi Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 92. Shionogi Recent Development Table 93. Otsuka Pharmaceutical Company Information Table 94. Otsuka Pharmaceutical Business Overview Table 95. Otsuka Pharmaceutical Anxiety Disorders And Depression Therapeutic Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Otsuka Pharmaceutical Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 97. Otsuka Pharmaceutical Recent Development Table 98. Merck & Co. Inc Company Information Table 99. Merck & Co. Inc Business Overview Table 100. Merck & Co. Inc Anxiety Disorders And Depression Therapeutic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Merck & Co. Inc Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 102. Merck & Co. Inc Recent Development Table 103. Lundbeck Company Information Table 104. Lundbeck Business Overview Table 105. Lundbeck Anxiety Disorders And Depression Therapeutic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Lundbeck Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 107. Lundbeck Recent Development Table 108. Kanghong Pharma Company Information Table 109. Kanghong Pharma Business Overview Table 110. Kanghong Pharma Anxiety Disorders And Depression Therapeutic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Kanghong Pharma Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 112. Kanghong Pharma Recent Development Table 113. Bristol-Myers Squibb Company Company Information Table 114. Bristol-Myers Squibb Company Business Overview Table 115. Bristol-Myers Squibb Company Anxiety Disorders And Depression Therapeutic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Bristol-Myers Squibb Company Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 117. Bristol-Myers Squibb Company Recent Development Table 118. APOTEX Company Information Table 119. APOTEX Business Overview Table 120. APOTEX Anxiety Disorders And Depression Therapeutic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. APOTEX Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 122. APOTEX Recent Development Table 123. Allergan Company Information Table 124. Allergan Business Overview Table 125. Allergan Anxiety Disorders And Depression Therapeutic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Allergan Anxiety Disorders And Depression Therapeutic Drug Product Portfolio Table 127. Allergan Recent Development Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Anxiety Disorders And Depression Therapeutic Drug Product Image Figure 2. Global Anxiety Disorders And Depression Therapeutic Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anxiety Disorders And Depression Therapeutic Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Anxiety Disorders And Depression Therapeutic Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Anticonvulsants Image Figure 8. Atypical Antipsychotics Image Figure 9. Benzodiazepines Image Figure 10. Beta-Blockers Image Figure 11. TeCAs Image Figure 12. TCAs Image Figure 13. SSRIs Image Figure 14. SNRIs Image Figure 15. MAOIs Image Figure 16. Others Image Figure 17. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type (2021-2032) Figure 20. Phobia Image Figure 21. Obsessive-Compulsive Disorder (OCD) Image Figure 22. Major Depressive Disorder (MDD) Image Figure 23. Others Image Figure 24. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application (2021-2032) Figure 27. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Anxiety Disorders And Depression Therapeutic Drug Sales Value (2021-2032) & (US$ Million) Figure 30. North America Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Anxiety Disorders And Depression Therapeutic Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Anxiety Disorders And Depression Therapeutic Drug Sales Value (2021-2032) & (US$ Million) Figure 36. South America Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Anxiety Disorders And Depression Therapeutic Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Years Considered Figure 124. Research Process Figure 125. Key Executives Interviewed

Scope & coverage.

Types
  • Anticonvulsants
  • Atypical Antipsychotics
  • Benzodiazepines
  • Beta-Blockers
  • TeCAs
  • TCAs
  • SSRIs
  • SNRIs
  • MAOIs
  • Others
Applications
  • Phobia
  • Obsessive-Compulsive Disorder (OCD)
  • Major Depressive Disorder (MDD)
  • Others
Companies covered
  • Takeda
  • Sanofi
  • Johnson & Johnson
  • Eli Lilly
  • Pfizer
  • GSK
  • AstraZeneca
  • Zhejiang Huahai
  • Shionogi
  • Otsuka Pharmaceutical
  • Merck & Co. Inc
  • Lundbeck
  • Kanghong Pharma
  • Bristol-Myers Squibb Company
  • APOTEX
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anxiety Disorders And Depression Therapeutic Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anxiety Disorders And Depression Therapeutic Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Anxiety Disorders And Depression Therapeutic Drug Market Dynamics
  1. 2.1 Anxiety Disorders And Depression Therapeutic Drug Industry Trends
  2. 2.2 Anxiety Disorders And Depression Therapeutic Drug Industry Drivers
  3. 2.3 Anxiety Disorders And Depression Therapeutic Drug Industry Opportunities and Challenges
  4. 2.4 Anxiety Disorders And Depression Therapeutic Drug Industry Restraints
3 Anxiety Disorders And Depression Therapeutic Drug Market by Company
  1. 3.1 Global Anxiety Disorders And Depression Therapeutic Drug Company Revenue Ranking in 2025
  2. 3.2 Global Anxiety Disorders And Depression Therapeutic Drug Revenue by Company (2021-2026)
  3. 3.3 Global Anxiety Disorders And Depression Therapeutic Drug Company Ranking (2024-2026)
  4. 3.4 Global Anxiety Disorders And Depression Therapeutic Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Anxiety Disorders And Depression Therapeutic Drug Company Product Type and Application
  6. 3.6 Global Anxiety Disorders And Depression Therapeutic Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Anxiety Disorders And Depression Therapeutic Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Anxiety Disorders And Depression Therapeutic Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Anxiety Disorders And Depression Therapeutic Drug Market by Type
  1. 4.1 Anxiety Disorders And Depression Therapeutic Drug Type Introduction
  2. 4.1.1 Anticonvulsants
  3. 4.1.2 Atypical Antipsychotics
  4. 4.1.3 Benzodiazepines
  5. 4.1.4 Beta-Blockers
  6. 4.1.5 TeCAs
  7. 4.1.6 TCAs
  8. 4.1.7 SSRIs
  9. 4.1.8 SNRIs
  10. 4.1.9 MAOIs
  11. 4.1.10 Others
  12. 4.2 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Type
  13. 4.2.1 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Type (2021-2032)
  15. 4.2.3 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type (2021-2032)
5 Anxiety Disorders And Depression Therapeutic Drug Market by Application
  1. 5.1 Anxiety Disorders And Depression Therapeutic Drug Application Introduction
  2. 5.1.1 Phobia
  3. 5.1.2 Obsessive-Compulsive Disorder (OCD)
  4. 5.1.3 Major Depressive Disorder (MDD)
  5. 5.1.4 Others
  6. 5.2 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Application
  7. 5.2.1 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application (2021-2032)
6 Anxiety Disorders And Depression Therapeutic Drug Regional Value Analysis
  1. 6.1 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anxiety Disorders And Depression Therapeutic Drug Sales Value (2021-2032)
  7. 6.3.2 North America Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Anxiety Disorders And Depression Therapeutic Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Anxiety Disorders And Depression Therapeutic Drug Sales Value (2021-2032)
  16. 6.6.2 South America Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Anxiety Disorders And Depression Therapeutic Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Country, 2025 VS 2032
7 Anxiety Disorders And Depression Therapeutic Drug Country-level Value Analysis
  1. 7.1 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Anxiety Disorders And Depression Therapeutic Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Anxiety Disorders And Depression Therapeutic Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Anxiety Disorders And Depression Therapeutic Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GSK
  32. 8.6.1 GSK Company Information
  33. 8.6.2 GSK Business Overview
  34. 8.6.3 GSK Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GSK Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  36. 8.6.5 GSK Recent Developments
  37. 8.7 AstraZeneca
  38. 8.7.1 AstraZeneca Company Information
  39. 8.7.2 AstraZeneca Business Overview
  40. 8.7.3 AstraZeneca Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  42. 8.7.5 AstraZeneca Recent Developments
  43. 8.8 Zhejiang Huahai
  44. 8.8.1 Zhejiang Huahai Company Information
  45. 8.8.2 Zhejiang Huahai Business Overview
  46. 8.8.3 Zhejiang Huahai Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Zhejiang Huahai Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  48. 8.8.5 Zhejiang Huahai Recent Developments
  49. 8.9 Shionogi
  50. 8.9.1 Shionogi Company Information
  51. 8.9.2 Shionogi Business Overview
  52. 8.9.3 Shionogi Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shionogi Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  54. 8.9.5 Shionogi Recent Developments
  55. 8.10 Otsuka Pharmaceutical
  56. 8.10.1 Otsuka Pharmaceutical Company Information
  57. 8.10.2 Otsuka Pharmaceutical Business Overview
  58. 8.10.3 Otsuka Pharmaceutical Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Otsuka Pharmaceutical Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  60. 8.10.5 Otsuka Pharmaceutical Recent Developments
  61. 8.11 Merck & Co. Inc
  62. 8.11.1 Merck & Co. Inc Company Information
  63. 8.11.2 Merck & Co. Inc Business Overview
  64. 8.11.3 Merck & Co. Inc Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Merck & Co. Inc Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  66. 8.11.5 Merck & Co. Inc Recent Developments
  67. 8.12 Lundbeck
  68. 8.12.1 Lundbeck Company Information
  69. 8.12.2 Lundbeck Business Overview
  70. 8.12.3 Lundbeck Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Lundbeck Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  72. 8.12.5 Lundbeck Recent Developments
  73. 8.13 Kanghong Pharma
  74. 8.13.1 Kanghong Pharma Company Information
  75. 8.13.2 Kanghong Pharma Business Overview
  76. 8.13.3 Kanghong Pharma Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Kanghong Pharma Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  78. 8.13.5 Kanghong Pharma Recent Developments
  79. 8.14 Bristol-Myers Squibb Company
  80. 8.14.1 Bristol-Myers Squibb Company Company Information
  81. 8.14.2 Bristol-Myers Squibb Company Business Overview
  82. 8.14.3 Bristol-Myers Squibb Company Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bristol-Myers Squibb Company Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  84. 8.14.5 Bristol-Myers Squibb Company Recent Developments
  85. 8.15 APOTEX
  86. 8.15.1 APOTEX Company Information
  87. 8.15.2 APOTEX Business Overview
  88. 8.15.3 APOTEX Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 APOTEX Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  90. 8.15.5 APOTEX Recent Developments
  91. 8.16 Allergan
  92. 8.16.1 Allergan Company Information
  93. 8.16.2 Allergan Business Overview
  94. 8.16.3 Allergan Anxiety Disorders And Depression Therapeutic Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Allergan Anxiety Disorders And Depression Therapeutic Drug Product Portfolio
  96. 8.16.5 Allergan Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst